Latest News

• share
• favorite_border

Findings suggest a new approach to treat early heart failure

• share
• favorite_border

Search for new inflammatory disease drugs may be aided by detailed structure of distinct ubiquitin ligase complex

• share
• favorite_border

Letizia Amadini-Lane takes key position at SBP

• share
• favorite_border

Team of scientists from the Icahn School of Medicine at Mount Sinai and Sanford Burnham Prebys Medical Discovery Institute among those who combined large genomic and proteomic datasets to identify novel host targets to treat flu

• share
• favorite_border

Dietary fucose supplementation found to suppress the growth of melanoma

• share
• favorite_border

The first-in-class compound halts tumor growth by disrupting protein production

• share
• favorite_border

Doug Lewandowski will deepen the Institute’s cardiovascular disease expertise and direct Cardiovascular Translational Research.

• share
• favorite_border

SBP researchers combine publicly available cancer databases to identify new genes associated with cancer

• share
• favorite_border

SBP researchers and colleagues discover a mechanism that regulates the aging and abundance of secreted proteins

• share
• favorite_border

An emerging class of drugs called Smac mimetics may lead to a safe and effective treatment to eradicate HIV.

• share
• favorite_border

The appoptosin protein initiates a path that leads to the accumulation of tau, a key component of brain lesions.

• share
• favorite_border

The findings introduce new drug targets to selectively inhibit a key event in tumor cell progression.

• share
• favorite_border

In a collaborative study between Sanford Burnham Prebys Medical Discovery Institute (SBP) and the Argonne National Laboratory, scientists have used a highly specialized X-ray crystallography technique to solve the protein structure of hypoxia-inducible factors (HIFs), important regulators of a tumor’s response to low oxygen (hyopoxia).

• share
• favorite_border

Sanford Burnham Prebys Medical Discovery Institute’s Graduate School of Biomedical Sciences receives WASC accreditation

• share
• favorite_border

Study suggests that drugs targeting the lymphotoxin-beta receptor may improve liver cancer treatment.

• share
• favorite_border

Sanford Burnham Prebys Medical Discovery Institute (SBP) at Lake Nona today announced that the first funded company established based on work emerging from SBP’s Orlando campus, micro-gRx Incorporated, has received a $200,000 award from Space Florida through the Florida – Israel Innovation Partnership Program.

• share
• favorite_border

Sanford-Burnham Medical Research Institute announced today that it has received a gift of $100 million from prominent San Diego philanthropist Conrad Prebys. This is the largest donation ever made by Prebys and will be used to further implement the Institute’s 10-year strategic vision.

• share
• favorite_border

In a scientific discovery that has significant implications for preventing HIV infections, researchers at Sanford-Burnham Medical Research Institute have identified a protein that could improve the body’s immune response to HIV vaccines and prevent transmission of the virus.

• share
• favorite_border

Study explains why some melanoma tumors are resistant to BRAF inhibitor treatment

• share
• favorite_border

Sanford-Burnham Medical Research Institute at Lake Nona (Sanford-Burnham) today announced it has signed a two-year partnership agreement with Takeda Pharmaceutical Company Ltd. (Takeda) of Japan to study the potential role of several gene regulatory proteins as targets for the treatment of heart failure.

• share
• favorite_border

Sanford-Burnham Medical Research Institute (Sanford-Burnham) today announced the election of two new members to its Board of Trustees. The Board will grow to 23 members with the addition of the following new Trustees:

• share
• favorite_border

Scientists find a novel avenue for therapeutic intervention of the “silent cancer.”

• share
• favorite_border

Sanford-Burnham Medical Research Institute (Sanford-Burnham) today announced that it has signed a licensing agreement to further develop a first-in-class small molecule with Daiichi Sankyo for the treatment of cardiovascular-metabolic disease. The small molecule is based on longstanding, groundbreaking biology work by a Sanford-Burnham scientist and his laboratory team, who for decades focused their research on treating a consequence of cardiovascular-metabolic disease.

• share
• favorite_border

Researchers identify a control mechanism for glutamine uptake in breast cancer cells and its importance for response to select chemotherapies.

• share
• favorite_border

Sanford-Burnham Medical Research Institute at Lake Nona today announced that Michael Ayers has joined the Institute as associate director of Government Relations. In this role, he will develop and execute strategies to fortify Sanford-Burnham’s leadership role within Florida’s emerging life-sciences industry. Michael’s scope of responsibilities includes working with the Florida legislature, U.S. Congress, as well as state and federal government agencies to advance the Institute’s mission at its Lake Nona campus. Ayers will report to the vice president of Public Affairs.

• share
• favorite_border

Researchers find that melanoma cells are dependent on a source of glutamine for growth irrespective of the mutation(s) that drive the cancer.

• share
• favorite_border

Researchers identify signaling molecules in intestinal stem cells that can lead to tumors if left unregulated. The findings suggest a new approach to targeting intestinal cancers.

• share
• favorite_border

In a new study from Sanford-Burnham Medical Research Institute, researchers have used human pluripotent stem cells to generate new hair. The study represents the first step toward the development of a cell-based treatment for people with hair loss. In the United States alone, more than 40 million men and 21 million women are affected by hair loss. The research was published online in PLOS One yesterday.

• share
• favorite_border

• share
• favorite_border

Erkki Ruoslahti and Kristiina Vuori have been named NAI Fellows—a professional distinction accorded to academic inventors who have demonstrated a prolific spirit of innovation.